Belite Bio (BLTE) Stock: Buy, Sell, or Hold?
BLTE - Belite Bio, Inc American Depositary Shares
$147.33
-2.94 (-1.96%)
▼
5d:
+3.19%
30d:
-13.05%
90d:
-7.01%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
15d
Get Alerted When BLTE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BLTE shows positive signals but monitor for confirmation. Market pricing in 23.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BLTE shows positive signals but monitor for confirmation. Market pricing in 23.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$79.17
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$49.16
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BLTE is currently trading at $147.33, which is considered oversold relative to its 30-day fair value range of $151.65 to $169.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 65.2) compared to its historical average (148.0). Remarkably, the market is currently pricing in an annual earnings decline of 23.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BLTE is in a uptrend. Immediate support is located at $141.62, while resistance sits at $161.00.
Market Sentiment: BLTE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $228.89 (+55.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BLTE is in a uptrend. Immediate support is located at $141.62, while resistance sits at $161.00.
Market Sentiment: BLTE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $228.89 (+55.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$151.65 -
$169.76
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 55.4% below Wall St target ($228.89)
- BULLISH: Bottoming setup score 60/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$151.65 -
$169.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$141.62
Resistance Level
$161.00
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
65.19
Wall Street Target
$228.89
(+55.4%)
Valuation Discount vs History
-23.9% cheaper
PE vs Historical
65.2 vs 148.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-23.9%
(market-implied from PE analysis)
1-Year Target
$132.60
(-10%)
2-Year Target
$119.34
(-19%)
3-Year Target
$107.40
(-27%)
3-Yr Target (if PE normalizes)
(PE: 65→148)
$243.84
(+66%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 65.2 to 148.0
Stabilization Target:
$334.48
(+127.0%)
PE Expansion Potential:
+127.0%
Share & Embed Analysis
Last updated: October 23, 2026 9:54 PM ET
Data refreshes hourly during market hours. Next update: 10:54 PM
Data refreshes hourly during market hours. Next update: 10:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLTE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 35 SELL |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 65 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 47 HOLD |
